Kenacort Retard

Triamcinolone acetonide, the active ingredient in Kenacort Retard, is a corticosteroid presented as a sterile suspension for intramuscular or intra‑articular injection. It is used to reduce inflammation in musculoskeletal and dermatologic conditions in adult patients. The formulation provides prolonged release of the drug at the injection site, allowing sustained anti‑inflammatory effect.

GNH USA supplies Kenacort Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global logistics for this product.

Kenacort Retard, a corticosteroid injection, is employed in several inflammatory and immune‑mediated conditions.

- Rheumatoid arthritis: reduces joint swelling, pain and stiffness. - Osteoarthritis: alleviates synovitis and improves joint function. - Bursitis: decreases local inflammation and discomfort. - Psoriasis and eczema (intralesional): suppresses skin immune response and clears lesions. - Severe allergic asthma exacerbations: mitigates airway inflammation when administered systemically.

Adverse reactions to Kenacort Retard can vary in frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Transient hyperglycemia: temporary rise in blood glucose, especially in diabetic patients. - Facial flushing: brief redness of the face or neck. - Mild gastrointestinal upset: nausea or dyspepsia.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production with prolonged use. - Osteonecrosis: rare bone tissue death, particularly in weight‑bearing joints. - Severe infection: increased susceptibility to bacterial, viral or fungal infections.

Before using Kenacort Retard, consider the following precautions to minimize risk.

- Assess infection risk: avoid injection in patients with active systemic infections. - Monitor glucose: check blood sugar levels in diabetic patients. - Screen for osteoporosis: use caution in patients with reduced bone density. - Avoid in pregnancy unless clearly needed: potential fetal effects. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Kenacort Retard may interact with other medicines; awareness of key interactions helps ensure safety.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors (e.g., ketoconazole): may increase corticosteroid levels and toxicity. - Live vaccines: risk of disseminated infection due to immunosuppression. - Anticoagulants (e.g., warfarin): heightened bleeding risk from mucosal thinning.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive gastrointestinal irritation. - Diuretics (e.g., furosemide): may exacerbate hypokalemia. - Antidiabetic agents: possible need for dose adjustment due to hyperglycemia.